Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 295-300

  Ralston, S H ^a   Thiebaud D ^b   Herrmann, Z ^c   Steinhauer, E U ^d   Thurlimann B ^e   Walls, J ^f   Lichinitser, M R ^g   Rizzoli, R ^h   Hagberg, H ⁱ   Huss, H J ^c   Tubiana Hulin, M ^j   Body, J J ^k  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d KLINIKUM KASSEL   (Germany)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f University Hospital   (United Kingdom)

^g N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^h UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^j CENTRE RENÉ HUGUENIN   (France)

^k JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

Bisphosphonate; Cancer; Hypercalcaemia; Parathyroid hormone related protein; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 8044222736     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.48     Document Type: Article

References (31)

1. Body JJ (1992) Bone metastases and tumor induced hypercalcemia. Curr Opin Oncol 4: 624-631
2. Body JJ and Dumon JC (1994) Treatment of tumor-induced hypercalcemia with the bisphosphonate pamidronate: dose-response relationship and influence of the tumour type. Ann Oncol 5: 359-363
3. Body JJ, Pot M, Borkowski A, Sculier JP and Klastersky J (1987) Dose-response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Med 82: 957-963
4. Bonjour J, Guelpa PG, Bisetti A, Rizzoli R, Jung A, Rosini S and Kanis JA (1988) Bone and renal components of hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 9: 123-130
5. Fleisch H (1991) Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 42: 919-944
6. Fleisch H (1993) Bisphosphonates in Bone Disease. Stampfli: Berne.
7. Gallacher SJ, Fraser WD, Patel U, Logue FC, Soukop M, Boyle IT and Ralston SH (1990) Breast-cancer associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem 27: 551-556
8. Grill V, Ho P, Body JJ, Johanson N, Kukreja SC, Moseley JM and Martin TJ (1991) Parathyroid hormone related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73: 1309-1315
9. Gurney H, Kefford R and Stuart-Harris R (1989) Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet 1: 241-244
10. Isales C, Carcangui ML and Stewart AF (1987) Hypercalcemia in breast cancer: a re-evaluation. Am J Med 82: 1143-1147
11. Martin TJ and Suva LJ (1989) Parathyroid hormone-related protein in hypercalcaemia of maligancy. Clin Endocrinol 31: 631-647
12. Mundy GR and Martin TJ (1982) The hypercalcemia of malignancy: pathogenesis and management. Metabolism 131: 1247-1277
13. Mundy GR, Wilkinson R and Heath DA (1983) Comparative study of the available medical therapy for hypercalcaemia of malignancy. Am J Med 74: 421-432
14. Mühlbauer RC, Bauss F, Schenk M, Janner M, Bosies E, Strein K and Fleisch H (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003-1011
15. Nordin BEC, Horsman A and Aaron J (1976) Diagnostic procedures. In Calcium Phosphate and Magnesium Metabolism. Nordir BEC (ed.) Churchill Livingstone: Edinburgh pp. 473-474
16. Nussbaum SR, Warrell RP, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbach SD and Gertz BJ (1993a) Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 11: 1618-1623
17. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC and Mallete LE (1993b) Single dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60- and 90-mg dosages. Am J Med 95: 297-304
18. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D and Kanis JA (1993) Effective treatment of maligant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 67: 560-563
19. Percival RC, Yates AJP, Gray RES, Galloway J, Rogers K, Neal FE and Kanis JA (1985) Mechanisms of malignant hypercalcaemia in carcinoma of the breast. Br Med J 291: 776-779
20. Ralston SH (1987) The pathogenesis of humoral hypercalcaemia of malignancy. Lancet 2: 1443-1446
21. Ralston SH (1991) Pathogenesis and management of hypercalcaemia. In Bone Metastases: Diagnosis and Treatment. Rubens RD and Fogelman I (eds). Springer-Verlag: London, pp. 99-117
22. Ralston SH (1992) Medical management of hypercalcaemia. Br J Clin Pharmacol 34: 11-20
23. Ralston SH, Cowan RA, Mckillop JH, Gardner MD and Boyle IT (1987) Mechanisms of hypercalcaemia and response to antihypercalcemic therapy in malignancy. Bone Miner 2: 227-242
24. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA and Boyle IT (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 2: 1180-1182
25. Ralston SH, Gallacher SJ, Patel U, Campbell J and Boyle IT (1990) Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med 112: 499-504
26. Thiebaud D, Jaeger P, Jacquet AF and Burckhardt P (1986) A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate. J Bone Miner Res 6: 555-562
27. Thiebaud D, Jaeger P and Burckhardt P (1990) Response to retreatment of malignant hypercalcemia with bisphosphonate AHPrBP (APD): respective role of kidney and bone. J Bone Miner Res 5: 221-226
28. Warrell RP, Bockman RS, Coonley CJ, Isaacs M and Staszewski H (1984) Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487-1490
29. Warrell RP, Murphy WK, Schulman PJ and O'Dwyer PJ (1990) Gallium nitrate for treatment of cancer-related hypercalcemia: a randomized double-blind comparison to etidronale. J Clin Oncol 9: 65-69
30. Wuster C, Schoter KH, Thiebaud D, Manegold C, Krahl D, Clemens MR, Ghielmini M, Jaeger P and Scharla SH (1993) Methylpentylaminohydroxypropylidenebisphosphonate (BM 21.0955): a new potent and safe hisphosphonate for the treatment of cancer-associated hypercalcaemia. Bone Miner 22: 77-85
31. Yates AJP, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW and Mundy GR (1988) Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J Clin Invest 81: 932-938